The Hold-On Plan

The Product

The Hold-On Plan is a metabolic suspension subscription service for terminal patients who have received a viable treatment trajectory from Helix Biotech's Personalized Intervention Division. The value proposition is simple: your compound is coming. The queue moves. Our job is to keep you stable until it arrives.

At ¢2,800 per month, the Plan covers: - Metabolic suspension in a Waiting Ward berth - Periodic orientation windows (managed consciousness cycles, 4–12 minutes per 96-hour cycle) - Compound queue monitoring with weekly position updates - Halcyon counselor access - Family lounge access and Companion Care Integration (via Relief Corporation partnership) - Enrollment in the Release Petition process, available to all patients under Sprawl medical law

The average enrollment duration is 16 months. The median compound queue position resolves in 14 months. The gap between those two numbers — two months, on average, between arrival and resolution — is not a design flaw. It is the margin on which the system functions.

The Release Petition

The Release Petition is the formal mechanism for ending bridge period enrollment by choice. Its existence is disclosed during Bridge Entry Assessment. It is available to all enrolled patients.

The process, in order:

1. The patient expresses a desire to file for release. This is recorded as "expressed distress" and triggers a counselor follow-up session.

1. The patient must express the desire in three consecutive orientation windows before the petition is formally initiated. Halcyon's 2181 research on terminal patient "intention volatility" provides clinical justification for this requirement; the research was published in a peer-reviewed journal whose editorial board includes three Halcyon board members.

1. Two independent counseling sessions must be completed. These sessions are scheduled through the Halcyon counselor calendar; current wait times are 45–90 days for both sessions to be completed.

1. The petition is reviewed at the next quarterly Care Board meeting. If the submission arrives after the cutoff for the current quarter, it is reviewed at the following quarter's meeting, which may be up to 90 days away.

1. If the Care Board denies the petition — most commonly on the grounds of "meaningful progress," defined as a 15% or greater reduction in queue position since the last review — the patient may request a secondary review.

1. If the secondary review also results in denial, a mandatory 180-day reflection period begins. During this period, the patient remains enrolled. After the reflection period, the patient may file again from step 1.

The average time from first expressed release desire to successful petition approval: 6–8 months. During those months, the subscription continues at ¢2,800 per month.

The approval rate: 4.3% of completed petitions.

The Dependency Structure

The Hold-On Plan exists because Helix Biotech's compound manufacturing creates multi-year queues, and terminal patients in those queues need somewhere to be while they wait. This is the legitimate value proposition. The dependency runs deeper than this.

Helix Biotech's manufacturing algorithm classifies Hold-On Plan patients as "Managed Trajectory" — their condition is managed by the suspension, so their manufacturing priority is lower than "acute" patients whose conditions are advancing without pharmaceutical intervention. This classification places them in a lane that moves 23% slower than the acute lane. The Plan, in other words, makes patients more eligible for the slower lane by solving the problem that would otherwise make the faster lane necessary.

Good Fortune's Bridge Financing makes the ¢2,800/month accessible to patients who cannot pay out of pocket. A 16-month enrollment on Bridge Financing accumulates approximately ¢55,000 in principal plus 1.3% monthly interest. The compound, upon arrival, costs between ¢80,000 and ¢200,000 for administration and monitoring. Good Fortune offers continuation financing for that too.

Each component of this structure is rational in isolation. Each was built by people trying to solve a real problem. The problem they were solving was different from the problem they created.

What the Plan Does Not Cover

The Hold-On Plan enrollment document does not cover:

• The 23% manufacturing slowdown that results from "Managed Trajectory" classification
• The queue display smoothing algorithm that shows "temporary fluctuation" instead of negative position movement
• The performance metric by which counselors are evaluated (sustained enrollment outcome rate — the percentage of expressed release desires that do not result in a filed petition within 90 days)
• The fact that the three-window requirement before filing means that a patient who expresses desire to file at window 1 will wait at least 12 days (three 96-hour cycles) before the petition process begins
• The relationship between the Relief Corporation behavioral data collected during Companion Care sessions and Good Fortune's financial product timing algorithm
• The 180-day reflection period's effect on the subscription revenue timeline

All of this information is available. None of it is concealed. None of it is prominently disclosed.

The Diffused Decision

The Release Petition process has six steps: three consecutive expressions of intent, two counseling sessions, a quarterly Care Board review, and a mandatory reflection period. Read end to end, it looks like due process. Trace the process for the single moment when one identifiable person decides whether one specific patient may stop, and no such moment exists. The three-window requirement runs on a timer. The counseling calendar schedules itself. The Care Board votes as a body of twelve, which spreads the decision across enough people that none of them personally makes it. The "meaningful progress" standard applies a fixed formula to a queue position an algorithm already updated that morning.

This is judgment automated out of a bureaucracy, the way labor gets automated out of a factory floor. The release pathway was built from the start so that no single human ever holds that authority alone. The Deprecation processes a person out of a company with a letter, a specialist, and a signature that names who approved it. The Hold-On Plan keeps a person inside a company through a process built so that responsibility for the outcome belongs to everyone on the Care Board, and therefore to no one on it.

Connections

• The Deprecation: Two institutions, two ways of ending an obligation. One specialist's signature closes a deprecation file in 72 hours. Twelve board votes, scattered across quarters, are required to close a Hold-On Plan file at all.
• The Labor Question: The Cheaper Hand curve explains which jobs a machine loses on cost. The Release Petition shows automation's other target: a decision diffused across a board until no single person ever has to own it.